Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
Four patients did not take the fourth dose of Vivotif as the box of pills was lost; Case reference number US-BN-2024-001737 is a spontaneous case report initially received from a nurse via Med Communication (reference number: USBAV24-0596) on 29-Mar-2024 and concerns four patients of unspecified age or gender. The patients' medical history and concomitant medication details were not provided. On an unspecified dates, the patients took first, second and third doses of Vivotif (batch number: unknown) at an unknown dose, orally, for unknown indication. As reported, the patients were supposed to take the fourth dose of Vivotif on 29-Mar-2024, however the four patients did not take the fourth dose as the box of pills was lost (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown whether the patients experienced any adverse event due to Vivotif. No further information was provided.; Reporter's Comments: Four patients of unspecified age or gender were supposed to take the fourth dose of Vivotif on 29-Mar-2024, however the patients did not take the fourth dose as the box of pills was lost, which is considered as inappropriate schedule of vaccine administered. It was unknown whether the patients experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patients' medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: Four patients of unspecified age or gender were supposed to take the fourth dose of Vivotif on 29-Mar-2024, however the patients did not take the fourth dose as the box of pills was lost, which is considered as inappropriate schedule of vaccine administered. It was unknown whether the patients experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patients' medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.